Vincerx Pharma, Inc. (VINC)
NASDAQ: VINC · IEX Real-Time Price · USD
0.640
-0.037 (-5.41%)
At close: Nov 28, 2023, 4:00 PM
0.692
+0.052 (8.08%)
After-hours: Nov 28, 2023, 6:13 PM EST
Vincerx Pharma Stock Forecast
Stock Price Forecast
According to 2 stock analysts, the average 12-month stock price forecast for Vincerx Pharma stock is $4.00, which predicts an increase of 524.80%. The lowest target is $3.00 and the highest is $5.00. On average, analysts rate Vincerx Pharma stock as a strong buy.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 7, 2023.
Analyst Ratings
The average analyst rating for Vincerx Pharma stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '23 | Jul '23 | Aug '23 | Sep '23 | Oct '23 | Nov '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $5 | Buy | Reiterates | $5 | +681.01% | Sep 7, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | +368.60% | Nov 17, 2022 |
| SVB Leerink | SVB Leerink | Buy Maintains $6 → $5 | Buy | Maintains | $6 → $5 | +681.01% | Aug 12, 2022 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $22 → $8 | Buy | Maintains | $22 → $8 | +1,149.61% | Jun 8, 2022 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $12 → $6 | Strong Buy | Maintains | $12 → $6 | +837.21% | Jun 7, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.03
from -3.11
EPS Next Year
-0.45
from -2.03
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 913,500 | 7.9M |
| Avg | n/a | n/a | n/a | 887,400 | 7.7M |
| Low | n/a | n/a | n/a | 852,600 | 7.4M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | - | - | - | - | 793.4% |
| Avg | - | - | - | - | 767.8% |
| Low | - | - | - | - | 733.8% |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | -1.67 | -0.42 | -0.30 | -0.45 | -0.44 |
| Avg | -2.03 | -0.45 | -0.30 | -0.44 | -0.43 |
| Low | -2.22 | -0.47 | -0.28 | -0.42 | -0.41 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.